ARCHIVES

Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

April 6, 2012

Tri-Institutional Stem Cell Initiative Funds Grants.

August 4, 2006

NCI Bypass Budget Calls For $5.98 Billion

December 6, 2002

FDA to Move Away From Central Radiology To Investigator Review In PFS Endpoint Trials

July 27, 2012

CIS Celebrates 15th Anniversary, Praised By M. Quayle

December 6, 1991

Firm Begins Phase II Trial Of LDP-341 For Myeloma.

March 30, 2001